Cleemput I., Franken M., Koopmanschap M., Polain M., European Drug Reimbursement Systems’ Legitimacy: Five-‑Country Comparisoan and Policy Tool. „International Journal of Technology Assessment in Health Care” 2012; 28, 4: 1–9.

U.S. Department of Health and Human Services, Startegic Plan Fiscal year 2010–2015. Department of Health and Human Services, Washington, DC 2010.

High Level Group on Health Services and Medical Care, Background document setting out health system objectives of particular interest to different European committees. European Commission, Surrey 2004.

Araszkiewicz A. (red.), Biała Księga, Osoby chorujące na schizofrenię w Polsce, Raport 2011: 6–35.

Decollogny A., Eggli Y., Halfon P., Lufkin TM., Determinants of generic drug substitution in Switzerland. „BMC Health Service Research” 2011; 11, 17 doi: 10.1186/1472-6963-11-17.

Andersson K., Bergström G., Petzold M.G., Carlsten A., Impact of a generic substitution reform on patients’ and society’s expenditure for pharmaceuticals. „Health Policy” 2007; 81, 2–3: 376–384.

Himmel W., Simmenroth-Nayda A., Niebling W., Ledig T., Jansen R.D., Kochen M.M., Gleiter C.H., Hummers-Pradier E., What do primary care patients think about generic drugs? „International Journal of Clinical Pharmacology and Therapeutics” 2005; 43, 10: 472–479.

Hassali M.A., Shafie A.A., Jamshed S., Ibrahim M.I., Awaisu A., Consumers’ views on generic medicines: a review of the literature. „International Journal of Pharmacy Practice” 2009; 17, 2: 79–88.

Shrank W H., Hoang T., Ettner S.L., Glassman P.A., Nair K., DeLapp D., Dirstine J., Avorn J., Asch S.M., The implications of choice: prescribing generic or preferred pharmaceutical improves medication adherence for chronic conditions. „Archives of Internal Medicine” 2006; 166, 3: 332–337.

Heikkilä R., Mäntyselkä P., Hartikainen-Herranen K., Ahonen R., Customers’ and physicians’ opinions of and experiences with generic substitution during the first year in Finland. „Health Policy” 2007; 82, 3: 366–374.

Granlund D., Are private physicians more likely to veto generic substitution of prescribed pharmaceuticals? „Social Sciences & Medicine” 2009; 69, 11: 1643–1650.

Magliano L., Fiorillo A., Malangone C., Aletti A., Belotti G., Bevilacqua P., Delle Femine A.L., Fontana G., Maucioni F., Travi M., Zanus P., Rossi A., Maj M., Family burden in schizophrenia: effects of socio-environmental and clinical variables and family intervention. „Epidemiologia e Psichiatria Sociale” 1998; 7, 3: 178–187.

Magliano L., Fadden G., Economou M., Xavier M., Held T., Guarneri M., Marasco C., Tosini P., Maj M., Social and clinical factors influencing the choice of coping strategies in relatives of patients with schizophrenia: results of the BIOMED I study. „Social Psychiatry and Psychiatric Epidemiology” 1998; 33, 9: 413–419.

Magliano L., Fadden G., Madianos M., de Almeida J.M., Held T., Guarneri M., Marasco C., Tosini P., Maj M., Burden on the families of patients with schizophrenia: results from the BIOMED I study. „Social Psychiatry and Psychiatric Epidemiology” 1998; 33, 9: 405–412.

Daltio D.S., Mari J.J., Ferraz M.B., Direct medical costs associated with schizophrenia relapses in health care services in the city of Sao Paulo. „Revista Saude Publica” 2011; 45, 1: 14–23.

Weiden P.J., Olfson M., Cost of relapse in schizophrenia. „Schizophrenia Bulletin” 1995; 21, 3: 419–429.

Sun S.X., Liu G.G., Christensen D.B., Fu A.Z., Review and analysis of hospitalization costs associated with antipsychotics nonadherence in the treatment of schizophrenia in the United States. „Current Medical Research & Opinion” 2007; 23, 10: 2305–2312.

Rummel-Kluge Ch., Pitschel-Walz G., Bäuml J., Kissling W., Psychoeducation in Schizophrenia – Results of a Survey of All Psychiatric Institutions in Germany, Austria, and Switzerland. „Schizophrenia Bulletin” 2006; 32, 4: 765–775

Weiden P., Glazer W., Assessment and treatment selection for „revolving door” inpatients with schizophrenia. „The Psychiatric Quarterly” 1997; 68, 4: 377–392.

Czernikiewicz A., Łoza B,. Znaczenie współpracy w terapii schizofrenii. Efektywność i bezpieczeństwo risperidonu stosowanego w formie długo działającej iniekcji. Neuropsychiatria. „Przegląd Kliniczny” 2010; 2, 1: 17–22.

Olivares J.M., Peuskens J., Pecenak J., Resseler S., Jacobs A., Akhras K.S., e-STAR Study Group, Clinical and resourceuse outcomes of risperidone long-acting injection  in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. „Current Medical Research & Opinion” 2009; 25, 9: 2197–2206.